1174632-70-2

Upstream product

• 261763-37-5 2,3-difluoro-4-methylbenzoic acid 

Downstream Products

• 1436422-13-7 (R)-4-((1-amino-3-hydroxy-1-oxopropan-2-ylamino)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluorobenzamide 
• 1436421-68-9 4-(((2H-tetrazol-5-yl)methylamino)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluorobenzamide 
• 1436426-81-1 tert-butyl 4-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzyl)-3-(2-methoxy-2-oxoethyl)piperazine-1-carboxylate 
• 1436422-04-6 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-4-((2-cyanoethylamino)methyl)-2,3-difluorobenzamide 
• 1436422-09-1 4-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzyl)piperazine-1-carboxamide 
• 1436422-59-1 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluoro-4-((4-(hydroxymethyl)piperidin-1-yl)methyl)benzamide 
• 1436421-76-9 2-(1-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzyl)pyrrolidin-3-yl)acetic acid 
• 1436421-77-0 3-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzylamino)propanoic acid 
• 1436421-80-5 2-((4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-2,3-difluorobenzyl)(methyl) amino)acetic acid 
• 1436422-14-8 (S)-4-(((1-amino-3-hydroxy-1-oxopropan-2-yl)(ethyl)amino)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2,3-difluorobenzamide hydrochloride 
• 1436426-26-4 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-4-(chloromethyl)-2,3-difluorobenzamide 

Relevant academic research and scientific papers

Xofluza sulfur-containing heterocyclic compound, intermediate and preparation method thereof

The invention discloses an Xofluza sulfur-containing heterocyclic compound, an intermediate and a preparation method thereof, and provides a preparation method of a compound represented by a formula 5. The preparation method is mild in reaction condition,

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the Mas receptor, and are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune system, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. These diseases and disorders include, for example, vascular disorders, such as: coronary heart disease, atherosclerosis, ischemia, reperfusion injury, angina pectoris, myocardial infarction, the no-reflow phenomenon, hypertension, transient ischemic attack, ischemic colitis, mesenteric ischemia, acute limb ischemia, and skin discoloration caused by reduced blood flow to the skin; and calcium-signaling disorders such as: arrhythmia, tachycardia, bradycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, Wolff-Parkinson-White syndrome, ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation, reperfusion arrhythmia, and reperfusion-induced cardiomyocyte cell death.

MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR

The present invention provides a novel thiazole derivative useful as a VAP-1 inhibitor, a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.